What is the half-life of Xgeva (denosumab)?
Xgeva (denosumab) has a reported effective half-life of about 25 days (roughly 3–4 weeks). This value reflects the drug’s behavior with repeated dosing in patients. [1][2]
How does Xgeva dosing affect “half-life” in practice?
Because denosumab is given as a fixed schedule (for example, every 4 weeks for many indications), the “effective half-life” is often discussed in terms of how quickly drug levels decline between doses rather than as a single simple timer. With regular dosing, concentrations reach a steady state, and the practical time course is governed by that ~25-day effective half-life. [1]
Is the half-life the same in cancer and bone-loss indications?
The effective half-life is generally treated as consistent across the product’s clinical uses, though individual factors (such as kidney function, overall health, and concomitant medications) can affect dosing decisions and safety monitoring. The published pharmacokinetic description for denosumab’s effective half-life remains around 25 days. [1][2]
Where does the half-life come from in the labeling?
The half-life figure is based on pharmacokinetic evaluation described in clinical/pharmacology information for denosumab (Xgeva), which distinguishes the “effective” half-life from more theoretical estimates. That’s why you may see the number presented as an effective half-life rather than a purely mathematical elimination half-life. [1][2]
Sources
[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/125320s017lbl.pdf
[2] https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-informationen.pdf